Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
Recruitment status was Recruiting
In this study we intend to compare the effect of Sertindole to that of Risperidone on cognitive impairment in schizophrenia.
Hypothesis: Sertindole will be as effective as Risperidone for treating cognitive impairment in schizophrenia and with fewer side effects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone|
- cognitive functioning [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Discontinuation due to all causes, symptomatology and adverse events. [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||October 2008|
|Estimated Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
Other Name: Serdolect
|Active Comparator: Risperidone||
Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00480844
|Contact: Mark Weiser, Drfirstname.lastname@example.org|
|Department of Psychiatry of the Sheba Medical Center||Recruiting|
|Ramat Gan, Tel Hashomer, Israel, 52621|
|Contact: Mark Weiser, Dr 03-5303773 email@example.com|
|Principal Investigator: Mark Weiser, Dr|
|Beer-Yaakov Mental Health Center||Not yet recruiting|
|Beer-Yaakov, Israel, 70350|
|Principal Investigator: Yehuda Abramowitz, Dr|
|Kfar Shaul Mental Health Center||Not yet recruiting|
|Jerusalem, Israel, 91060|
|Principal Investigator: Alexander Teitelbaum, Dr|
|Principal Investigator:||Mark Weiser, Dr||Shaba Medical Center, Tel-Aviv University Sackler School of Medicine|